Please login to the form below

Memorial Sloan Kettering

This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.

Armoured CAR ‘could overwhelm solid tumour resistance’

Memorial Sloan Kettering Cancer Center's Renier Brentiens. The team, led by Renier Brentjens of Memorial Sloan Kettering Cancer Center in the US, modified CAR-T cells designed to seek out ... Eureka and Memorial Sloan Kettering have been working together

Latest news

US insurers can peg access to ICER value reviews

Earlier this week, US industry body the Pharmaceutical Research and Manufacturers of America (PhRMA) highlighted a study by Memorial Sloan Kettering Cancer Center researchers in a blog post, which “reinforces that
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

For OSE, the deal gives it another partnership with a large pharma partner, adding to collaborations with Memorial Sloan Kettering Cancer Centre in the US and biotech Selexis on immuno-oncology,
Gilead adds to CAR-T assets with Cell Design Labs buyout

It’s an exciting time, ”said Renier Brentjens, medical oncologist and director of cellular therapeutics at Memorial Sloan Kettering Cancer Centre.
Keytruda claims first blood cancer OK from FDA

fight against this devastating disease," said Craig Moskowitz, clinical director of the division of haematologic oncology, Memorial Sloan Kettering Cancer Centre in the US.
Takeda launches drug discovery biotech

It builds on work from the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) - a partnership created in 2013 by the Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill ... We're tapping into the distinguished talent

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine
José Baselga joins BMS’ board of directors

Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and
OncoMed’s CMO steps down

Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Getting personal with wearable tech

In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Sudler London - Account Director: Competitive

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director or Senior Account Director: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Graduate Scientific Editor: DOE

Sudler London - Senior Medical Writer: Competitive

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director, Healthcare Advertising Agency: Salary TBC

Medical Writers Required - Hertfordshire: Competitive

Market Access Consultant - Greater Manchester: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Healthcare PR Senior Account Manager: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Subscribe to our email news alerts

PMHub

Add my company

Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....